Was waiting the worst part?
On December 29, the US Food and Drug Administration (FDA) finalized long-awaited biosimilar guidance from 2014 on the needed clinical pharmacology data from pharmaceutical sponsors.
“Clinical pharmacology studies are part of a stepwise approach for developing the data and information needed to support a demonstration of biosimilarity,” said the FDA. “These studies can reduce the residual uncertainty in assessing the biosimilarity between a proposed biosimilar product and reference product and inform the design of subsequent clinical trials to assess clinically meaningful differences.”
The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created the original approval pathway for follow-on biologics, and guidance on interchangeability is expected this year, containing recommendations on how clinical pharmacology studies that assess the presence or absence of clinically meaningful differences between the proposed biosimilar and the reference product should be conducted and analyzed.
There are four areas upon which the new guidance focuses:
It has been a long 20 months for drug manufacturers who have been awaiting the update to the original draft version, and had taken issue with the FDA's four possible outcomes and terminology for the analytical comparison of the reference product and proposed biosimilar drug.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.